Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
  • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/08—Tripeptides
  • C07K5/0802—Tripeptides with the first amino acid being neutral
  • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
  • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/20—Antivirals for DNA viruses
  • A61P31/22—Antivirals for DNA viruses for herpes viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

• the present invention relates to macrocyclic compounds that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, the synthesis of such compounds, and the use of such compounds for treating HCV infection and/or reducing the likelihood or severity of HCV infection.
• HCV hepatitis C virus
• HCV infection is a major health problem that leads to chronic liver disease, such as cirrhosis and hepatocellular carcinoma, in a substantial number of infected individuals.
• Current treatments for HCV infection include immunotherapy with recombinant interferon- ⁇ alone or in combination with the nucleoside analog ribavirin.
• NS3 metal loprotease
• NS3 serine protease
• NS3 a helicase
• NS5B RNA- dependent RNA polymerase
• the NS3 protease is located in the N-terminal domain of the NS3 protein.
• NS4A provide a cofactor for NS3 activity.
• the present invention relates to a macrocyclic compound of formula (I) and pharmaceutically acceptable salts thereof.
• the compound and its salts are HCV NS3 protease inhibitors.
• the compound and its salts have therapeutic and research applications.
• a first aspect of the present invention describes a compound of formula (I), or a pharmaceutical acceptable salt thereof:
• the present invention also includes pharmaceutical compositions containing a compound of the present invention and methods of preparing such pharmaceutical compositions.
• the present invention further includes methods of treating or reducing the likelihood or severity of HCV infection.
• the present invention includes a compound of formula (I), and pharmaceutically acceptable salts thereof.
• the compound and its pharmaceutically acceptable salts are useful in the inhibition of HCV NS3 protease, the treatment of HCV infection and/or the reduction of the likelihood or severity of an HCV infection.
• Prophylactic applications include, for example, treatment after suspected past exposure to HCV by such means as blood transfusion, exchange of body fluids, bites, accidental needle stick, or exposure to patient blood during surgery.
• the compounds and salts may be the primary active therapeutic agent.
• the compound may be combined with other therapeutic agents including but not limited to other HCV antivirals, anti-infectives, immunomodulators, antibiotics or vaccines.
• NS3 inhibitors are also useful in the preparation and execution of screening assays for antiviral compounds.
• such compounds can be used to isolate enzyme mutants, which are excellent screening tools for more powerful antiviral compounds.
• the compounds may be used to establish or determine the binding site of other antivirals to HCV protease, e.g., by competitive inhibition.
• Example 2 the formula (I) compound was compared to the compound of Examples 110 and 118 of WO 2008/057209, and has several advantages. WO 2008/057209 is not admitted to be prior art to the claimed invention.
• composition comprising an effective amount of a compound of formula (I) and a pharmaceutically acceptable carrier.
• composition of (a) further comprising a second therapeutic agent selected from the group consisting of HCV antiviral agents, immunomodulators, and anti-infective agents.
• HCV antiviral agent is an antiviral selected from the group consisting of HCV protease inhibitors and HCV NS5B polymerase inhibitors.
• a pharmaceutical combination which is (i) a compound of formula (I) and (ii) a second therapeutic agent selected from the group consisting of HCV antiviral agents, immunomodulators, and anti-infective agents; wherein the compound of formula (I) and the second therapeutic agent are each employed in an amount that renders the combination effective for inhibiting HCV NS3 protease, or for treating HCV infection and/or reducing the likelihood or severity of HCV infection.
• HCV antiviral agent is an antiviral selected from the group consisting of HCV protease inhibitors and HCV NS5B polymerase inhibitors.
• HCV antiviral agent is an antiviral selected from the group consisting of HCV protease inhibitors and HCV NS5B polymerase inhibitors.
• (j) A method of inhibiting HCV NS3 protease in a subject in need thereof which comprises administering to the subject the pharmaceutical composition of (a), (b), or (c) or the combination of (d) or (e).
• (k) A method of treating HCV infection and/or reducing the likelihood or severity of HCV infection in a subject in need thereof which comprises administering to the subject the pharmaceutical composition of (a), (b), or (c) or the combination of (d) or (e).
• Reference to a compound also includes stable complexes of the compound such as a stable hydrate.
• a “stable” compound is a compound which can be prepared and isolated and whose structure and properties remain or can be caused to remain essentially unchanged for a period of time sufficient to allow use of the compound for the purposes described herein (e.g., therapeutic or prophylactic administration to a subject).
• administration means providing the compound or a prodrug of the compound to the individual in need of treatment
• administration means providing the compound or a prodrug of the compound to the individual in need of treatment
• active agents e.g., antiviral agents useful for treating HCV infection
• administration and its variants are each understood to include concurrent and sequential provision of the compound or salt and other agents.
• the compounds of the present invention may be administered in the form of pharmaceutically acceptable salts.
• pharmaceutically acceptable salt refers to a salt of the parent compound which has activity and which is not biologically or otherwise undesirable (e.g., is neither toxic nor otherwise deleterious to the recipient thereof).
• Suitable salts include acid addition salts which may, for example, be formed by mixing a solution of a compound with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, acetic acid, trifluoroacetic acid, or benzoic acid.
• Compounds carrying an acidic moiety can be mixed with suitable pharmaceutically acceptable salts to provide, for example, alkali metal salts (e.g., sodium or potassium salts), alkaline earth metal salts (e.g., calcium or magnesium salts), and salts formed with suitable organic ligands such as quaternary ammonium salts.
• suitable pharmaceutically acceptable salts for example, alkali metal salts (e.g., sodium or potassium salts), alkaline earth metal salts (e.g., calcium or magnesium salts), and salts formed with suitable organic ligands such as quaternary ammonium salts.
• suitable pharmaceutically acceptable esters can be employed to modify the solubility or hydrolysis characteristics of the compound.
• prodrug is intended to encompass an inactive drug form or compound that is converted into an active drug form or compound by the action of enzymes, chemicals or metabolic processes in the body of an individual to whom it is administered.
• composition is intended to encompass a product comprising the specified ingredients, as well as any product which results, directly or indirectly, from combining the specified ingredients.
• pharmaceutically acceptable is meant that the ingredients of the pharmaceutical composition must be compatible with each other and not deleterious to the recipient thereof.
• subject refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
• an effective amount indicates a sufficient amount to exert a therapeutic or prophylactic effect.
• an effective amount is sufficient to achieve one or more of the following effects: reduce the ability of HCV to replicate, reduce HCV load, and increase viral clearance.
• an effective amount is sufficient to achieve one or more of the following: a reduced susceptibility to HCV infection, and a reduced ability of the infecting virus to establish persistent infection for chronic disease.
• the compounds of the present invention can be administered by means that produces contact of the active agent with the agent's site of action. They can be administered by conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can be administered alone, but typically are administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
• Compounds can, for example, be administered by one or more of the following routes: orally, parenterally (including subcutaneous injections, intravenous, intramuscular, intrastemal injection or infusion techniques), by inhalation (such as in a spray form), or rectally, in the form of a unit dosage of a pharmaceutical composition containing an effective amount of the compound and conventional non-toxic pharmaceutically-acceptable carriers, adjuvants and vehicles.
• Liquid preparations suitable for oral administration e.g., suspensions, syrups, elixirs and the like
• Solid preparations suitable for oral administration e.g.
• powders, pills, capsules and tablets can be prepared according to techniques known in the art and can employ such solid excipients as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like.
• Parenteral compositions can be prepared according to techniques known in the art and typically employ sterile water as a carrier and optionally other ingredients, such as solubility aids.
• injectable solutions can be prepared according to methods known in the art wherein the carrier comprises a saline solution, a glucose solution or a solution containing a mixture of saline and glucose. Further guidance for methods suitable for use in preparing pharmaceutical compositions of the present invention and of ingredients suitable for use in said compositions is provided in Remington's Pharmaceutical Sciences, 20 th edition (ed. A. R. Gennaro, Mack Publishing Co., 2000).
• the compounds of this invention can be administered orally in a dosage range of 0.001 to 1000 mg/kg of mammal (e.g., human) body weight per day in a single dose or in divided doses.
• mammal e.g., human
• One dosage range is 0.01 to 500 mg/kg body weight per day orally in a single dose or in divided doses.
• Another dosage range is 0.1 to 100 mg/kg body weight per day orally in single or divided doses.
• the compositions can be provided in the form of tablets or capsules containing 1.0 to 500 mg of the active ingredient, particularly 1, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, 500, and 750 mg of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
• the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
• the quinoxaline macrocyclic compounds described herein can be used in a combination treatment involving one or more additional therapeutic agents.
• Additional therapeutic agents include those also targeting HCV, targeting a different disease causing agent, or those enhancing the immune system.
• Agents enhancing the immune system include those generally enhancing an immune system function and those producing a specific immune response against HCV.
• Additional therapeutic agents targeting HCV include agents targeting NS3 and agents targeting other HCV activities such as NS5A and NS5B, and agents targeting host cell activities involved in HCV replication.
• HCV inhibitors are described in different publications. Macrocyclic compounds useful as inhibitors the HCV protease inhibitors are described in WO 06/119061, WO 7/015785, WO 7/016441, WO 07/148135, WO 08/051475, WO 08/051477, WO 08/051514, WO 08/057209.
• HCV NS3 protease inhibitors are disclosed in International Patent Application Publications WO 98/22496, WO 98/46630, WO 99/07733, WO 99/07734, WO 99/38888, WO 99/50230, WO 99/64442, WO 00/09543, WO 00/59929, WO 02/48116, WO 02/48172, British Patent No. GB 2 337 262, and U.S. Patent No. 6,323,180.
• therapeutic agents that may be present in a combination include ribavirin, levovirin, viramidine, thymosin alpha- 1, interferon- ⁇ , interferon- ⁇ , pegylated interferon- ⁇ (peginterferon- ⁇ ), a combination of interferon- ⁇ and ribavirin, a combination of peginterferon- ⁇ and ribavirin, a combination of interferon- ⁇ and levovirin, and a combination of peginterferon- ⁇ and levovirin.
• Interferon- ⁇ includes recombinant interferon- ⁇ 2a (such as ROFERON interferon available from Hoffmann-LaRoche, Nutley, NJ), pegylated interferon- ⁇ 2a (PEGASYS), interferon- ⁇ 2b (such as INTRON-A interferon available from Schering Corp., Kenilworth, NJ), pegylated interferon- ⁇ z2b (PEGINTRON), a recombinant consensus interferon (such as interferon al ⁇ hacon-1), and a purified interferon- ⁇ product.
• Amgen's recombinant consensus interferon has the brand name INFERGEN.
• Levovirin is the L-enantiomer of ribavirin which has shown immunomodulatory activity similar to ribavirin.
• Viramidine represents an analog of ribavirin disclosed in WO 01/60379.
• the individual components of the combination can be administered separately at different times during the course of therapy or concurrently in divided or single combination forms.
• Ribavirin, levovirin, and viramidine may exert their anti-HCV effects by modulating intracellular pools of guanine nucleotides via inhibition of the intracellular enzyme inosine monophosphate dehydrogenase (IMPDH).
• IMPDH inosine monophosphate dehydrogenase
• Ribavirin is readily phosphorylated intracellularly and the monophosphate derivative is an inhibitor of IMPDH.
• inhibition of IMPDH represents another useful target for the discovery of inhibitors of HCV replication.
• the compounds of the present invention may also be administered in combination with an inhibitor of IMPDH, such as VX-497, which is disclosed in International Patent Application Publications WO 97/4121 1 and WO 01/00622; another IMPDH inhibitor, such as that disclosed in WO 00/25780; or mycophenolate mofetil. See A.C. Allison and E.M. Eugui, 44 (Suppl.) Agents Action 165 (1993).
• an inhibitor of IMPDH such as VX-497, which is disclosed in International Patent Application Publications WO 97/4121 1 and WO 01/00622
• another IMPDH inhibitor such as that disclosed in WO 00/25780
• mycophenolate mofetil See A.C. Allison and E.M. Eugui, 44 (Suppl.) Agents Action 165 (1993).
• the compounds of the present invention may also be administered in combination with the antiviral agent amantadine (1-aminoadamantane).
• amantadine 1-aminoadamantane
• the compounds of the present invention may also be administered in combination with the antiviral agent polymerase inhibitor R7128 (Roche).
• the compounds of the present invention may also be combined for the treatment of HCV infection with antiviral 2'-C-branched ribonucleosides disclosed in R. E. Harry-O'Kuru et al., 62 J. Org. Chem. 1754-59 (1997); M. S. Wolfe et al., 36 Tet. Lett. 761 1-14 (1995); U.S. Patent No. 3,480,613; and International Patent Application Publications WO 01/90121, WO 01/92282, WO 02/32920, WO 04/002999, WO 04/003000 and WO 04/002422; the contents of each of which are incorporated by reference in their entirety.
• Such 2'-C-branched ribonucleosides include, but are not limited to, 2'-C-methyl-cytidine, 2'-C-methyl-uridine, 2'-C- methyl-adenosine, 2'-C-methyl-guanosine, and 9-(2-C-methyl- ⁇ -D-ribofuranosyl)-2,6- diaminopurine, and the corresponding amino acid ester of the ribose C-2', C-3', and C-5' hydroxyls and the corresponding optionally substituted cyclic 1,3 -propanediol esters of the 5'- phosphate derivatives.
• the compounds of the present invention may also be combined for the treatment of HCV infection with other nucleosides having anti-HCV properties, such as those disclosed in International Patent Application Publications WO 02/51425, WO 01/79246, WO 02/32920, WO 02/48165 and WO2005/003147 (including Rl 656, (2'/?)-2'-deoxy-2'-fluoro-2'-C- methylcytidine, shown as compounds M on page 77); WO 01/68663; WO 99/43691; WO 02/18404 and WO2006/021341, and U.S.
• nucleosides having anti-HCV properties such as those disclosed in International Patent Application Publications WO 02/51425, WO 01/79246, WO 02/32920, WO 02/48165 and WO2005/003147 (including Rl 656, (2'/?)-2'-deoxy-2'-fluoro-2'-C- methylcytidine, shown as compounds M on page 77); WO 01/6
• Patent Application Publication US 2005/0038240 including 4'-azido nucleosides such as Rl 626, 4'-azidocytidine; U.S. Patent Application Publications US 2002/0019363, US 2003/0236216, US 2004/0006007 and US 2004/0063658; and International Patent Application Publications WO 02/100415, WO 03/026589, WO 03/026675, WO 03/093290, WO 04/011478, WO 04/013300 and WO 04/028481 ; the content of each is incorporated herein by reference in its entirety.
• the compounds of the present invention may also be administered in combination with an agent that is an inhibitor of HCV NS5B polymerase.
• HCV NS5B polymerase inhibitors that may be used as combination therapy include, but are not limited to, those disclosed in International Patent Application Publications WO 02/057287, WO 02/057425, WO 03/068244, WO 2004/000858, WO 04/003138 and WO 2004/007512; U.S. Patent No. 6,777,392 and U.S. Patent Application Publication US2004/0067901; the content of each is incorporated herein by reference in its entirety.
• Other such HCV polymerase inhibitors include, but are not limited to, valopicitabine (NM-283; Idenix) and 2 > -F-2'-beta-methylcytidine (see also WO 2005/003147).
• nucleoside HCV NS5B polymerase inhibitors that are used in combination with the present HCV NS3 protease inhibitors are selected from the following compounds: 4-amino-7- ⁇ 2-C-methyl- ⁇ -D-arabinofuranosyl)-7H-pyrrolo[2,3-cf)pyrimidine; 4- amino-7-(2-C-memyI-p ⁇ D-ribofuranosyl)-7H ⁇ vrmlot2,3- ⁇ pyrimidine; 4-methylamino-7-(2-C- methyl- ⁇ -D-ribofuranosyl)-7H-pyrrolo[2,3- ⁇ i]pyrimidine; 4-dimethylamino-7- ⁇ 2-C-methyl- ⁇ -D- rirx)furanosyl)-7H-pyrrolo[2,3-cf]pyiimidine; 4-cyclopropylarnino-7-(2-C-methyl- ⁇ -D- rirx)furanosyl)-7H-pyrrolo[2,3
• the compounds of the present invention may also be combined for the treatment of ⁇ CV infection with non-nucleoside inhibitors of ⁇ CV polymerase such as those disclosed in International Patent Application Publications WO 01/77091; WO 01/47883; WO 02/04425; WO 02/06246; WO 02/20497; WO 2005/016927 (in particular JTK003); the content of each is incorporated herein by reference in its entirety; and ⁇ CV-796 (Viropharma Inc.).
• non-nucleoside inhibitors of ⁇ CV polymerase such as those disclosed in International Patent Application Publications WO 01/77091; WO 01/47883; WO 02/04425; WO 02/06246; WO 02/20497; WO 2005/016927 (in particular JTK003); the content of each is incorporated herein by reference in its entirety; and ⁇ CV-796 (Viropharma Inc.).
• non-nucleoside HCV NS5B polymerase inhibitors that are used in combination with the present HCV NS 3 protease inhibitors are selected from the following compounds: 14-cyclohexyl-6-[2- ⁇ dimethylamino)ethyl]-7-oxo-5 > 6,7,8- tetrahydroindolo[2,l- ⁇ ][2,5]benzodiazocine-l 1-carboxylic acid; 14-cyclohexyl-6- ⁇ 2-morpholin- 4-ylethyl)-5,6,7,8-tetrahydroindolo[2,l- ⁇ ][2,5]benzodiazocine-l 1-carboxylic acid; 14- cyclohexyl-6-[2-(dimemylamino)ethyl]-3-methoxy-5,6,7,8-tetrahydroindolo[2,l- ⁇ ] [2,5]benzodiazocine-l 1-carboxylic acid;
• a NS3 protease time-resolved fluorescence (TRF) assay is ⁇ CV NS3 protease time-resolved fluorescence (TRF) assay as described below and in Mao et al,, Anal. Biochem. 373: 1-8, 2008 and International Patent Application Publication WO 2006/102087.
• a NS3 protease assay can be performed, for example, in a final volume of 100 ⁇ l assay buffer containing 50 mM ⁇ EPES, p ⁇ 7.5, 150 mM NaCl, 15 % glycerol, 0.15 % TRITON X-100, 10 mM DTT, and 0.1 % PEG 8000.
• NS3 and NS4A protease is pre-incubated with various concentrations of inhibitors in DMSO for 30 minutes. The reaction is initiated by adding the TRF peptide substrate (final concentration 100 nM). NS3 mediated hydrolysis of the substrate is quenched after 1 hour at room temperature with 100 ⁇ l of 500 mM MES, pH 5.5. Product fluorescence is detected using either a VICTOR V2 or FUSION fluorophotometer (Perkin Elmer Life and Analytical Sciences) with excitation at 340 nm and emission at 615 nm with a 400 ⁇ s delay. Testing concentrations of different enzyme forms are selected to result in a signal to background ratio (S/B) of 10-30. IC 50 values are derived using a standard four-parameter fit to the data. K 1 values are derived from IC 50 values using the following formula,
• ICs 0 Ki (1 + [S] / K M ), Eqn (l), where [S] is the concentration of substrate peptide in the reaction and K M is the Michaelis constant.
• the present invention also includes processes for making compounds of formula (I).
• the compounds of the present invention can be readily prepared according to the following reaction schemes and examples, or modifications thereof, using readily available starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variants which are themselves known to those of ordinary skill in this art. Other methods for preparing compounds of the invention will be readily apparent to the person of ordinary skill in the art in light of the following reaction schemes and examples. Unless otherwise indicated, all variables are as defined above. The following reaction schemes and examples serve only to illustrate the invention and its practice,
• Olefin metathesis catalysts include the following Ruthenium based species: F. Miller et al., 118 J. AM. CHEM. SOC. 9606 (1996); G. Kingsbury et al., 121 J. Am. Chem. Soc. 791 (1999); H. Scholl et al., 1 ORG. LETT. 953 (1999); U.S. Patent Application Publication US20O2/01O7138; K. Furstner et al., 64 J. ORG. CHEM. 8275 (1999).
• the utility of these catalysts in ring closing metathesis is well known in the literature (e.g. Trnka and Grubbs, 34 Ace. CHEM. RES. 18 (2001).
• Step 1 [(lEVhq ⁇ ta-L ⁇ -dien-l-yloxyJCtrimethvDsilane
• Step 2 /ro/ty-2-pent-4-en-l-ylcyclopropanol
• Step 3 methyl 3 -methyl -/'/-(oxomethyleneVL-valinate
• Step 4 methyl 3 -methyl -N-(If(I j? ⁇ 2J?)-2-pent-4-en-l-ylcvclopropyl]oxy)carbonyl)-L-valinate and methyl 3-methyl-N-( If(15 l ,2SV2-pent-4-en- 1 -ylcyclopropyll oxy ⁇ carbonylVL- valinate
• Step 3 1-ferr-butyl 2-methyl (2S,4R)-4-r(3-chloro-7-methoxyquinoxalin-2-yl)oxy1pyrrolidine- 1 ,2-dicarboxylate
• Step 4 methyl (4RM-[(3-chloro-7-methoxyqumoxdin-2- ⁇ l)oxy[-L-prolinate hydrochloride
• Step 1 methyl 3-methyl-N-( ⁇ [(lR,2R)-2-pent-4-en-l-ylcvclopropyl
• Step 3 methyl riaR.5S.8S.10R.18E.22aRV5-tert-butyl-14-methoxy-3.6-dioxo- l,la.3 ⁇ 5,6.9.10.20 ⁇ 1.22.22a-dodecahvdro-8H-7,10- methanocyclopropa[18J9in.l0.3,6]dioxadiazacvclononadecino[l lJ2-b1quinoxaline-8- carboxylate
• Step 4 methyl ⁇ aR.5S.8S.10R.22aRV5-tert-butyl-14-methoxy-3.6-dioxo- l.la.3.4.5.6.9.10.18.19.20.21.22 ⁇ 2a-tetradecahvdro-8H-7.10- methanocvclopropa[ 18 ⁇ 9) [ IJ 0,3 ⁇ Idioxadiazacvclononadecinor 11.12-b]quinoxaline-8- carbox ⁇ late
• Step 5 (laR,SS.8S.10It22aRVS-tert-but ⁇ l-14-methoxy-3.6-dioxo- l.la.3.4.5.6.9.10J 8.19 ⁇ 0 ⁇ U2 ⁇ 2a-tetradecahvdro-8H-7.10- methanocyclopropaf 18.191 f 1.10,3. ⁇ ldioxadiazacyclononadecinof 1 1,12-b1quinoxaline-8- carboxylic acid
• Step 6 (I aR.5S.8S.10R ⁇ 2aRV 5-tert-butyl-N-(f 1 RJ2SV 1 - ( [(cvclopropylsulfonvnaminol carbonvU-2-vinylcvclopropyl>-14-methoxy-3.6-dioxo-l.la.3.4,5.6,9.10.18J9,20 ⁇ 1 ⁇ 2 ⁇ 2a- tetradecahydro-8H-7, 10-methanocvclopropaf 18.191[Ll OJ ⁇ ldioxadiazacvclononadecinof 11.12- biquinoxaline-8-carbo ⁇ amide
• Example 1 The compound of Example 1 was compared to the compound of Examples 110 and 118 of WO 2008/057209. The results are shown in Tables 1 and 2 below. As illustrated in the tables and the discussion of the results, the compound of formula (I) appears to have several advantageous properties compared to both the WO 2008/057209 Example 1 18 compound and the WO 2008/057209 Example 110 compound.
• Ki Inhibition constant, reference to ⁇ 0.016 nM indicates that the observed activity is less than 0.016 nM, the exact amount less than 0.016 nM was not determined by the assay; EC50; Effective concentration achieving 50% viral replication suppression; gt: Genotype; AUC: Area Under the plasma concentration/time curve; LOQ: Limit of quantitation (3 pmol/mg); BLQ: Below limit of quantitation.
• Example 110 compound Advantageous properties of the formula (I) compound versus the WO 2008/057209
• Example 110 compound are the following: 1 ) Physical properties (no salt disproportionation for the Compound of formula (I));
• the differences in properties are particularly advantageous for the formulation and administration of the formula (I) compound compared to the WO 2008/057209 Example 1 10 compound.
• the lack of salt disproportionation for the formula (I) compound enables dissolution of 1.8 mg/ml of the K+ salt form of the Compound of Example 1 in water.
• the K+ salt form of the WO 2008/057209 Example 110 compound has improved aqueous solubility (9.7 mg/mL), the compound thus dissolved disproportionates to give a crystalline zwitterionic form which has low aqueous solubility ( ⁇ 0.009 mg/ml).
• Example 118 is its resistance profile against different mutant enzymes.
• HTV protease inhibitors e.g. HTV protease inhibitors
• HCV NS3 protease inhibitors e.g., VX -950, telaprevir
• the compound of Example 1 showed improved enzyme affinity (Ki) against different mutant enzymes that are known to confer resistance to HCV NS3 protease inhibitors.
• Table 2 summarizes activity against different mutant enzymes.
• an advantage of compound 1 may be an increased barrier to the development of resistant virus when administered to patients. It also provides the potential advantage to treat patients who have failed other therapies because of the development of resistance, since compound 1 may inhibit this resistant virus.
• Example 110 compound Further expected advantageous properties of the formula (I) compound versus the WO 2008/057209 Example 110 compound include the following:
• the formula (I) compound was found to have very good covalent binding in vivo characteristics and pharmacokinetic properties. Based on observed covalent binding in vivo and pharmacokinetic properties of the Example 1 compound and the WO 2008/057209 Example 118 compound, the formula (I) compound has significantly better in vivo covalent binding characteristics and pharmacokinetic properties .
• Example 1 showed undetectable binding to plasma proteins following oral administration of a single 20 mg/kg dose to rats. (See Table 1.) Under analogous conditions, the WO 2008/057209 Example 118 compound demonstrated detectable binding to rat liver proteins (see Table 1), and therefore may be considered a less advantageous compound for administration to human subjects than the compound of formula (I).
• Table 3 provides some additional in vivo covalent binding data observed for related compounds from WO 2008/057209 that contain the (R,R)-trans-2-alkylcyclopentanol moiety incorporated in Example 118.
• Target organ exposure in multiple preclinical species provides a rationale that high target organ exposure is achievable for the compound in patients, and high liver exposure in both rat and dog allows for confident evaluation of preclinical toxicity. High liver exposure is especially advantageous for HCV since this is the target organ for the drug.
• the compound of Example 1 had a very good rat plasma and liver exposure.
• the observed rat liver exposure was at a level greater than for WO 2008/057209 compound 118 and compound 1 10.
• Table 1 Based on these results and on testing several different compounds from WO 2008/057209 by oral administration to both rat (25mpk) and dog (5mpk), the compound of formula (I) is also expected to have dog liver exposures greater than WO2008/057209 compound 1 18 and compound 110.
• NS 3/4A Inhibitory Activity 1 (Ki): NS 3/4A Inhibitory Activity was determined as described in Section IV. Compound Evaluation supra., and Mao et al, Anal Biochem 373 ⁇ - 8, 2008.
• Rcplicon Activity 2 ECs ⁇ Replicon Activity was determined using the procedures described in Carroll et al, J. Biol. Chem. 278: ⁇ 1979-1 1984, 2003 and Olsen et al., ArUi Microb. Agents 4S-.3944-3953, 2004.
• Pharmacokinetic parameters were calculated based on non-compartmental analysis (e.g. using WATSON®, W ⁇ NNOL ⁇ N®). Predose concentrations that were below the limit of quantitation (BLQ) were assigned a value of 0. For oral AUC estimation, the first BLQ value in the terminal phase were given a value equal to 1 /2 Lowest Limit Of Quantitation, while subsequent values in the terminal phase were assigned a value of 0. Standard pharmacokinetic parameters CLp, Vdss, half-life (only for IV), % F, Cm ⁇ , Tm 8x , AUQ>-Ust > AUCo-. ⁇ finity were calculated. AUC values were calculated using linear trapezoidal method for ascending concentrations and the log trapezoidal method for descending concentrations.
• Counting of the plasma samples Place a 200 ⁇ L aliquot in a 20 mL scintillation vial. Add 500 ⁇ L of SOLVABLETM and incubate at 1 h with shaking at 55°C. Remove, allow to cool prior to the addition of 15 mL scintillation cocktail, and count. Plasma samples (200 ⁇ L aliquot) were then processed as described below for liver proteins.
• Tissue homogenization Weighed liver samples were diluted with 2 vol 100 mM phosphate buffer (pH 7.4) and homogenized on ice.
• Counting of the liver homogenate Aliquots were placed in a 20 mL scintillation vial, diluted with 1 mL of SOLVABLETM and incubated for 1 h with shaking at 55°C. After removal from the incubator and cooling 15 mL scintillation cocktail and 30% H 2 O 2 were added and the radioactivity counted Protein precipitation: Take 500 ⁇ L aliquot, add 1 :8 homogenate:acetonitrile (if compound is suspected to have low solubility in acetonitrile, another solvent may be selected), vortex and centrifuge (3500 rcf for 20 min). Discard the supernatant.
• Protein precipitate resuspension Sonication (minimal intensity, ⁇ 5 sec) and vortexing until the pellet crumbles in 80% MeOH: 20% water.
• Counting of the final pellet 1 mL of dissolved pellet, 15 mL scintillation cocktail (if another scintillation cocktail other than ULTIMA GOLDTM is used, pellet may require neutralization using 1 N HCl), and count.
• Protein concentration of the final pellet BCA or BlO-RAD kit using BSA as a standard.
• Counting of the dosing solution Count a known volume of the dosing solution in triplicate.
• Counting of the dosing solution count a known volume of the dosing solution in triplicate.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Virology (AREA)
• Molecular Biology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Engineering & Computer Science (AREA)
• Genetics & Genomics (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Biochemistry (AREA)
• Biophysics (AREA)
• Biotechnology (AREA)
• Gastroenterology & Hepatology (AREA)
• Epidemiology (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Peptides Or Proteins (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Priority Applications (26)

Applications Claiming Priority (2)

Publications (1)

Family

ID=41130248

Family Applications (1)

Country Status (43)

Cited By (24)

Families Citing this family (36)

Citations (4)

Family Cites Families (103)

• 2009
  • 2009-07-17 SI SI200930359T patent/SI2310095T1/sl unknown
  • 2009-07-17 EP EP12181533.6A patent/EP2540349B1/en active Active
  • 2009-07-17 PL PL09790553T patent/PL2310095T3/pl unknown
  • 2009-07-17 ME MEP-2012-463A patent/ME02024B/me unknown
  • 2009-07-17 KR KR1020117003982A patent/KR101313675B1/ko active Active
  • 2009-07-17 RS RS20120463A patent/RS52534B/sr unknown
  • 2009-07-17 EP EP09790553A patent/EP2310095B1/en active Active
  • 2009-07-17 CA CA2731177A patent/CA2731177C/en active Active
  • 2009-07-17 DK DK12181546.8T patent/DK2540350T3/da active
  • 2009-07-17 UA UAA201102068A patent/UA100436C2/uk unknown
  • 2009-07-17 EA EA201170241A patent/EA019327B1/ru active Protection Beyond IP Right Term
  • 2009-07-17 JP JP2011520110A patent/JP4920797B2/ja active Active
  • 2009-07-17 DK DK09790553.3T patent/DK2310095T3/da active
  • 2009-07-17 PT PT121815468T patent/PT2540350E/pt unknown
  • 2009-07-17 NZ NZ590638A patent/NZ590638A/en not_active IP Right Cessation
  • 2009-07-17 BR BRPI0916235A patent/BRPI0916235B8/pt active IP Right Grant
  • 2009-07-17 ME MEP-2014-375A patent/ME02132B/me unknown
  • 2009-07-17 PL PL12181546T patent/PL2540350T3/pl unknown
  • 2009-07-17 US US12/504,955 patent/US7973040B2/en active Active
  • 2009-07-17 SI SI200930956T patent/SI2540350T1/sl unknown
  • 2009-07-17 RS RS20140375A patent/RS53420B/sr unknown
  • 2009-07-17 PE PE2011000067A patent/PE20110212A1/es active IP Right Grant
  • 2009-07-17 ES ES12181546.8T patent/ES2491090T3/es active Active
  • 2009-07-17 MX MX2011000826A patent/MX2011000826A/es active IP Right Grant
  • 2009-07-17 MY MYPI20110310 patent/MY152070A/en unknown
  • 2009-07-17 AU AU2009274190A patent/AU2009274190B2/en active Active
  • 2009-07-17 PT PT09790553T patent/PT2310095E/pt unknown
  • 2009-07-17 CN CN200980137118.6A patent/CN102159285B/zh active Active
  • 2009-07-17 ES ES09790553T patent/ES2392611T3/es active Active
  • 2009-07-17 HR HRP20120866AT patent/HRP20120866T1/hr unknown
  • 2009-07-17 WO PCT/US2009/050915 patent/WO2010011566A1/en not_active Ceased
  • 2009-07-17 EP EP12181546.8A patent/EP2540350B1/en active Active
  • 2009-07-21 AR ARP090102779A patent/AR072588A1/es active IP Right Grant
  • 2009-07-21 TW TW098124597A patent/TWI441638B/zh active
• 2011
  • 2011-01-11 IL IL210580A patent/IL210580A/en active Protection Beyond IP Right Term
  • 2011-01-13 TN TN2011000014A patent/TN2011000014A1/fr unknown
  • 2011-01-19 CO CO11005448A patent/CO6351757A2/es active IP Right Grant
  • 2011-01-19 NI NI201100023A patent/NI201100023A/es unknown
  • 2011-01-20 SV SV2011003813A patent/SV2011003813A/es unknown
  • 2011-01-20 DO DO2011000023A patent/DOP2011000023A/es unknown
  • 2011-01-20 HN HN2011000209A patent/HN2011000209A/es unknown
  • 2011-01-21 CL CL2011000145A patent/CL2011000145A1/es unknown
  • 2011-01-21 EC EC2011010777A patent/ECSP11010777A/es unknown
  • 2011-01-25 MA MA33556A patent/MA32502B1/fr unknown
  • 2011-02-15 CR CR20110089A patent/CR20110089A/es unknown
  • 2011-05-20 US US13/112,281 patent/US8080654B2/en active Active
• 2012
  • 2012-11-28 CY CY20121101150T patent/CY1113752T1/el unknown
• 2014
  • 2014-07-18 HR HRP20140693AT patent/HRP20140693T1/hr unknown
  • 2014-08-01 CY CY20141100582T patent/CY1115503T1/el unknown
• 2016
  • 2016-12-26 FR FR16C1027C patent/FR16C1027I2/fr active Active
  • 2016-12-29 LT LTPA2016049C patent/LTC2310095I2/lt unknown
  • 2016-12-30 NL NL300857C patent/NL300857I2/nl unknown
• 2017
  • 2017-01-03 LU LU00002C patent/LUC00002I2/fr unknown
  • 2017-01-10 HU HUS1700001C patent/HUS1700001I1/hu unknown
  • 2017-01-20 NO NO2017004C patent/NO2017004I1/no unknown
  • 2017-01-20 CY CY2017005C patent/CY2017005I2/el unknown

Patent Citations (4)

Also Published As

Similar Documents

Legal Events